Jefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
From BiotechTV - News · 00:09:17
Show by BiotechTV
The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
More episodes of BiotechTV - News
More episodes
- Jefferies London 2026: Forbion, the most active lead investor in private biotech financing rounds globally last year, raised €2.3 billion across two new funds last month
- Jefferies London 2026: IDEAYA Biosciences Founder & CEO Yujiro Hata shares an update on darovasertib, which is in front of FDA for Uveal Melanoma, and talks DLL3 and PRMT5
- Jefferies London 2026: Zealand Pharma CEO Adam Steensberg gives an update on the company's amylin program and comments on recent data from its Boehringer partnered glucagon/GLP-1
- Jefferies London: When Celgene's powerhouse myeloma treatments emerged, it wasn't known that they were protein degraders. With today's advances in science, C4 aims to have a best in class degrader
- Jefferies London 2026: APOL1-mediated kidney disease affects over 1 million people in the United States - Maze Therapeutics hopes to deliver a solution
- Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27
- Jefferies London 2026: Erasca is racing to be the next big story in the RAS space (in both pancreatic and lung) and believes it may have a best in class asset with high potency
- Jefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
- Jefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
- Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
PodSearch is a free, independent podcast search engine. Read about PodSearch, the privacy policy or contact us.